Literature DB >> 21677109

Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activity.

Audun Aase1, Tove Karin Herstad, Samuel Merino, Merete Bolstad, Synne Sandbu, Hilde Bakke, Ingeborg S Aaberge.   

Abstract

Waning vaccine-induced immunity against Bordetella pertussis is observed among adolescents and adults. A high incidence of pertussis has been reported in this population, which serves as a reservoir for B. pertussis. A fifth dose of reduced antigen of diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine was given as a booster dose to healthy teenagers. The antibody activity against B. pertussis antigens was measured prior to and 4 to 8 weeks after the booster by different assays: enzyme-linked immunosorbent assays (ELISAs) of IgG and IgA against pertussis toxin (PT) and filamentous hemagglutinin (FHA), IgG against pertactin (PRN), opsonophagocytic activity (OPA), and IgG binding to live B. pertussis. There was a significant increase in the IgG activity against PT, FHA, and PRN following the booster immunization (P < 0.001). The prebooster sera showed a geometric mean OPA titer of 65.1 and IgG binding to live bacteria at a geometric mean concentration of 164.9 arbitrary units (AU)/ml. Following the fifth dose, the OPA increased to a titer of 360.4, and the IgG concentration against live bacteria increased to 833.4 AU/ml (P < 0.001 for both). The correlation analyses between the different assays suggest that antibodies against FHA and PRN contribute the most to the OPA and IgG binding.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21677109      PMCID: PMC3147361          DOI: 10.1128/CVI.05067-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  43 in total

1.  Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis.

Authors:  H E de Melker; F G Versteegh; M A Conyn-Van Spaendonck; L H Elvers; G A Berbers; A van Der Zee; J F Schellekens
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  Characterization of bactericidal immune responses following vaccination with acellular pertussis vaccines in adults.

Authors:  C L Weingart; W A Keitel; K M Edwards; A A Weiss
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

3.  Neutralizing antibodies to adenylate cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils.

Authors:  C L Weingart; P S Mobberley-Schuman; E L Hewlett; M C Gray; A A Weiss
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

4.  Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration.

Authors:  J Fernandez; O S Levine; J Sanchez; S Balter; L LaClaire; J Feris; S Romero-Steiner
Journal:  J Infect Dis       Date:  2000-10-09       Impact factor: 5.226

5.  [Should school children receive pertussis vaccine?].

Authors:  S Sandbu; H Nøkleby; O S Helland; B Feiring; M Bondevik; F Sundelin; J Storsaeter
Journal:  Tidsskr Nor Laegeforen       Date:  2001-05-10

Review 6.  Improving pertussis vaccination.

Authors:  Guy A M Berbers; Sabine C de Greeff; Frits R Mooi
Journal:  Hum Vaccin       Date:  2009-07-08

7.  A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.

Authors:  K Stehr; J D Cherry; U Heininger; S Schmitt-Grohé; M uberall; S Laussucq; T Eckhardt; M Meyer; R Engelhardt; P Christenson
Journal:  Pediatrics       Date:  1998-01       Impact factor: 7.124

8.  Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents.

Authors:  N N Tran Minh; Q He; A Ramalho; A Kaufhold; M K Viljanen; H Arvilommi; J Mertsola
Journal:  Pediatrics       Date:  1999-12       Impact factor: 7.124

9.  Seroepidemiology of Bordetella pertussis infections in the Spanish population: a cross-sectional study.

Authors:  P García-Corbeira; R Dal-Ré; L Aguilar; J García-de-Lomas
Journal:  Vaccine       Date:  2000-04-28       Impact factor: 3.641

10.  Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents.

Authors:  S L Hodder; J D Cherry; E A Mortimer; A B Ford; J Gornbein; K Papp
Journal:  Clin Infect Dis       Date:  2000-07-24       Impact factor: 9.079

View more
  5 in total

1.  Salivary IgA from the sublingual compartment as a novel noninvasive proxy for intestinal immune induction.

Authors:  A Aase; H Sommerfelt; L B Petersen; M Bolstad; R J Cox; N Langeland; A B Guttormsen; H Steinsland; S Skrede; P Brandtzaeg
Journal:  Mucosal Immunol       Date:  2015-10-28       Impact factor: 7.313

2.  Antibody-mediated complement C3b/iC3b binding to group B Streptococcus in paired mother and baby serum samples in a refugee population on the Thailand-Myanmar border.

Authors:  Jenny Herbert; Stephen Thomas; Charlotte Brookes; Claudia Turner; Paul Turner; Francois Nosten; Kirsty Le Doare; Michael Hudson; Paul T Heath; Andrew Gorringe; Stephen Taylor
Journal:  Clin Vaccine Immunol       Date:  2015-01-14

3.  Bordetella pertussis isolates vary in their interactions with human complement components.

Authors:  Charlotte Brookes; Irene Freire-Martin; Breeze Cavell; Frances Alexander; Stephen Taylor; Ruby Persaud; Norman Fry; Andrew Preston; Dimitri Diavatopoulos; Andrew Gorringe
Journal:  Emerg Microbes Infect       Date:  2018-05-09       Impact factor: 7.163

4.  Humanised monoclonal antibodies neutralise pertussis toxin by receptor blockade and reduced retrograde trafficking.

Authors:  Edith Acquaye-Seedah; Yimin Huang; Jamie N Sutherland; Andrea M DiVenere; Jennifer A Maynard
Journal:  Cell Microbiol       Date:  2018-09-23       Impact factor: 3.715

5.  Experimental infection of healthy volunteers with enterotoxigenic Escherichia coli wild-type strain TW10598 in a hospital ward.

Authors:  Steinar Skrede; Hans Steinsland; Halvor Sommerfelt; Audun Aase; Per Brandtzaeg; Nina Langeland; Rebecca J Cox; Marianne Saevik; Marita Wallevik; Dag Harald Skutlaberg; Marit Gjerde Tellevik; David A Sack; James P Nataro; Anne Berit Guttormsen
Journal:  BMC Infect Dis       Date:  2014-09-04       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.